Liquid biopsy specialist Angle announced a supplier agreement with AstraZeneca on Wednesday to develop and validate a methodology using Angle's existing DNA damage response (DDR) assay for the detection of micronuclei in circulating tumour cells (CTCs) as a measure of DDR.